Clinical Trial Update: Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) [Phase 1]

View source ↗

Summary

Phase 1 extension study update on repeated treatments with QLT091001 in people with Leber congenital amaurosis or retinitis pigmentosa; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis
• Retinitis Pigmentosa

Drugs mentioned

• QLT091001 (retinoid)

Snippet

Sponsor: QLT Inc. | Conditions: LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa) | Phase 1 | Status: COMPLETED